Literature DB >> 8405125

Interleukin-8 is chemotactic for vascular smooth muscle cells.

T L Yue1, P J Mckenna, J L Gu, G Z Feuerstein.   

Abstract

The chemotactic activity of interleukin-8 for human aortic smooth muscle cells was investigated in Transwell cell culture chamber using a polycarbonate membrane with pores of 8 microns. Interleukin-8 stimulated the smooth muscle cell migration time and dose dependently in the range between 10(-11) and 10(-8) M. At 10 nM of interleukin-8, the number of migrated smooth muscle cells increased by 40-fold over the basal level, and this stimulation was almost completely abolished by anti-interleukin-8 antibody. Checkerboard analysis showed that the response of smooth muscle cell to interleukin-8 was chemotactic. These results suggest that interleukin-8 may play a role in the pathogenesis of arterial intimal thickening and atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8405125     DOI: 10.1016/0014-2999(93)90549-w

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  10 in total

Review 1.  Interleukin-8 and its receptor CXCR2 in atherosclerosis.

Authors:  W A Boisvert; L K Curtiss; R A Terkeltaub
Journal:  Immunol Res       Date:  2000       Impact factor: 2.829

Review 2.  Sick fat: the good and the bad of old and new circulating markers of adipose tissue inflammation.

Authors:  I Barchetta; F A Cimini; G Ciccarelli; M G Baroni; M G Cavallo
Journal:  J Endocrinol Invest       Date:  2019-05-09       Impact factor: 4.256

3.  Pravastatin suppresses the interleukin-8 production induced by thrombin in human aortic endothelial cells cultured with high glucose by inhibiting the p44/42 mitogen activated protein kinase.

Authors:  M Takata; M Urakaze; R Temaru; K Yamazaki; N Nakamura; Y Nobata; M Kishida; A Sato; M Kobayashi
Journal:  Br J Pharmacol       Date:  2001-10       Impact factor: 8.739

4.  Interleukin 8 and susceptibility to coronary artery disease: a population genetics perspective.

Authors:  Konstantina Vogiatzi; Stavros Apostolakis; Vassilios Voudris; Sophia Thomopoulou; Georgios E Kochiadakis; Demetrios A Spandidos
Journal:  J Clin Immunol       Date:  2008-04-02       Impact factor: 8.317

5.  ACE inhibitor quinapril reduces the arterial expression of NF-kappaB-dependent proinflammatory factors but not of collagen I in a rabbit model of atherosclerosis.

Authors:  M A Hernández-Presa; C Bustos; M Ortego; J Tuñón; L Ortega; J Egido
Journal:  Am J Pathol       Date:  1998-12       Impact factor: 4.307

6.  CD4+ mononuclear cells induce cytokine expression, vascular smooth muscle cell proliferation, and arterial occlusion after endothelial injury.

Authors:  W W Hancock; D H Adams; L R Wyner; M H Sayegh; M J Karnovsky
Journal:  Am J Pathol       Date:  1994-11       Impact factor: 4.307

7.  The effects of interleukin-8 on airway smooth muscle contraction in cystic fibrosis.

Authors:  Vasanthi Govindaraju; Marie-Claire Michoud; Pasquale Ferraro; Janine Arkinson; Katherine Safka; Hector Valderrama-Carvajal; James G Martin
Journal:  Respir Res       Date:  2008-12-01

8.  Plasma interleukin 8 concentrations in obese subjects with impaired glucose tolerance.

Authors:  Marek Straczkowski; Irina Kowalska; Agnieszka Nikolajuk; Stella Dzienis-Straczkowska; Malgorzata Szelachowska; Ida Kinalska
Journal:  Cardiovasc Diabetol       Date:  2003-05-16       Impact factor: 9.951

9.  TNF-α in Combination with Palmitate Enhances IL-8 Production via The MyD88- Independent TLR4 Signaling Pathway: Potential Relevance to Metabolic Inflammation.

Authors:  Amal Hasan; Nadeem Akhter; Areej Al-Roub; Reeby Thomas; Shihab Kochumon; Ajit Wilson; Merin Koshy; Ebaa Al-Ozairi; Fahd Al-Mulla; Rasheed Ahmad
Journal:  Int J Mol Sci       Date:  2019-08-23       Impact factor: 5.923

10.  Arsenic exposure accelerates atherogenesis in apolipoprotein E(-/-) mice.

Authors:  Petia P Simeonova; Tracy Hulderman; Dan Harki; Michael I Luster
Journal:  Environ Health Perspect       Date:  2003-11       Impact factor: 9.031

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.